Conceptos Categóricos

Crónicas de autores

Ana M Aransay *

Autor invitado por SIIC

Esta investigación ha sido posible gracias a la colaboración de varias instituciones internacionales coordinadas por los proyectos HEPADIP y CIBERehd

EL PAPEL DEL TRANSPORTADOR SLC2A1 EN LA PATOGENIA DEL HÍGADO GRASO

A partir de un estudio de asociación de variantes genéticas, un consorcio internacional de investigadores relacionó ciertas mutaciones en el gen del transportador Glut1 (SLC2A1) con la aparición de enfermedad de hígado graso y demostró que la inhibición de este gen incrementa el almacenamiento de grasa en hepatocitos.

*Ana M Aransay
describe para SIIC los aspectos relevantes de su trabajo
SOLUTE CARRIER FAMILY 2 MEMBER 1 IS INVOLVED IN THE DEVELOPMENT OF NONALCOHOLIC FATTY LIVER DISEASE
Hepatology,
57(2):505-514 Feb, 2013

Esta revista, clasificada por SIIC Data Bases, integra el acervo bibliográfico
de la Biblioteca Biomédica (BB) SIIC.

Institución principal de la investigación
*Cic Biogune, Derio, España
Imprimir nota
Referencias bibliográficas
1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34:274-285, 2011.
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346:1221-1231, 2002.
3. Brunt EM. Nonalcoholic steatohepatitis (NASH): further expansion of this clinical entity? Liver 19:263-264, 1999.
4. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2:1048-1058, 2004.
5. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40:1461-1465, 2008.
6. Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, Gudnason V, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 7:e1001324, 2011.
7. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
8. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-1321, 2005.
9. Jorgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glumer C, Pisinger C. A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur J Cardiovasc Prev Rehabil 10:377-386, 2003.
10. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 24 Suppl 3:S6-11, 2000.
11. Barr J, Vazquez-Chantada M, Alonso C, Perez-Cormenzana M, Mayo R, Galan A, Caballeria J, et al. Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. J Proteome Res 9:4501-4512, 2010.
12. Rodriguez-Suarez E, Duce AM, Caballeria J, Martinez Arrieta F, Fernandez E, Gomara C, Alkorta N, et al. Non-alcoholic fatty liver disease proteomics. Proteomics Clin Appl 4:362-371, 2010.
13. Rubio A, Guruceaga E, Vazquez-Chantada M, Sandoval J, Martinez-Cruz LA, Segura V, Sevilla JL, et al. Identification of a gene-pathway associated with non-alcoholic steatohepatitis. J Hepatol 46:708-718, 2007.
14. Mato JM, Martinez-Chantar ML, Lu SC. Methionine metabolism and liver disease. Annu Rev Nutr 28:273-293, 2008.
15. Finkelstein JD, Martin JJ. Methionine metabolism in mammals. Distribution of homocysteine between competing pathways. J Biol Chem 259:9508-9513, 1984.
16. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81:559-575, 2007.
17. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, et al. The structure of haplotype blocks in the human genome. Science 296:2225-2229, 2002.
18. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265, 2005.
19. Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 25:386-401, 2001.
20. Pfeifer AM, Cole KE, Smoot DT, Weston A, Groopman JD, Shields PG, Vignaud JM, et al. Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. Proc Natl Acad Sci U S A 90:5123-5127, 1993.
21. Martinez-Lopez N, Varela-Rey M, Fernandez-Ramos D, Woodhoo A, Vazquez-Chantada M, Embade N, Espinosa-Hevia L, et al. Activation of LKB1-Akt pathway independent of phosphoinositide 3-kinase plays a critical role in the proliferation of hepatocellular carcinoma from nonalcoholic steatohepatitis. Hepatology 52:1621-1631, 2010.
22. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics 24:1547-1548, 2008.
23. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25:25-29, 2000.
24. Al-Shahrour F, Arbiza L, Dopazo H, Huerta-Cepas J, Minguez P, Montaner D, Dopazo J. From genes to functional classes in the study of biological systems. BMC Bioinformatics 8:114, 2007.
25. Fath MA, Diers AR, Aykin-Burns N, Simons AL, Hua L, Spitz DR. Mitochondrial electron transport chain blockers enhance 2-deoxy-D-glucose induced oxidative stress and cell killing in human colon carcinoma cells. Cancer Biol Ther 8:1228-1236, 2009.
26. Kessler RJ, Fanestil DD. Interference by lipids in the determination of protein using bicinchoninic acid. Anal Biochem 159:138-142, 1986.
27. Baylin A, Kabagambe EK, Siles X, Campos H. Adipose tissue biomarkers of fatty acid intake. Am J Clin Nutr 76:750-757, 2002.
28. Xu M, Wang W, Frontera JR, Neely MC, Lu J, Aires D, Hsu FF, et al. Ncb5or deficiency increases fatty acid catabolism and oxidative stress. J Biol Chem 286:11141-11154, 2011.
29. Redden DT, Allison DB. Nonreplication in genetic association studies of obesity and diabetes research. J Nutr 133:3323-3326, 2003.
30. Wang K, Li WD, Zhang CK, Wang Z, Glessner JT, Grant SF, Zhao H, et al. A genome-wide association study on obesity and obesity-related traits. PLoS One 6:e18939, 2011.
31. Noshiro M, Usui E, Kawamoto T, Sato F, Nakashima A, Ueshima T, Honda K, et al. Liver X receptors (LXRalpha and LXRbeta) are potent regulators for hepatic Dec1 expression. Genes Cells 14:29-40, 2009.
32. Gokey NG, Lopez-Anido C, Gillian-Daniel AL, Svaren J. Early growth response 1 (Egr1) regulates cholesterol biosynthetic gene expression. J Biol Chem 286:29501-29510, 2011.
33. Barbato A, Iacone R, Tarantino G, Russo O, Sorrentino P, Avallone S, Galletti F, et al. Relationships of PAI-1 levels to central obesity and liver steatosis in a sample of adult male population in southern Italy. Intern Emerg Med 4:315-323, 2009.
34. Hora C, Negro F, Leandro G, Oneta CM, Rubbia-Brandt L, Muellhaupt B, Helbling B, et al. Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C. Liver Int 28:370-376, 2008.
35. Jones KT, Greer ER, Pearce D, Ashrafi K. Rictor/TORC2 regulates Caenorhabditis elegans fat storage, body size, and development through sgk-1. PLoS Biol 7:e60, 2009.
36. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38:75-85, 2003.
37. Younossi ZM, Afendy A, Stepanova M, Hossain N, Younossi I, Ankrah K, Gramlich T, et al. Gene expression profile associated with superimposed non-alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C. Liver Int 29:1403-1412, 2009.
38. Chance B, Sies H, Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev 59:527-605, 1979.
39. Kc S, Carcamo JM, Golde DW. Vitamin C enters mitochondria via facilitative glucose transporter 1 (Glut1) and confers mitochondrial protection against oxidative injury. Faseb J 19:1657-1667, 2005.
40. Serviddio G, Bellanti F, Vendemiale G, Altomare E. Mitochondrial dysfunction in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 5:233-244, 2011.
41. Bilir BM, Gong TW, Kwasiborski V, Shen CS, Fillmore CS, Berkowitz CM, Gumucio JJ. Novel control of the position-dependent expression of genes in hepatocytes. The GLUT-1 transporter. J Biol Chem 268:19776-19784, 1993.
42. Rhoads DB. Liver GLUT-1 expression: an enigma deepens. Hepatology 19:540-542, 1994.
43. Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 16:5286-5296, 2010.
44. Lutoslawska G. Interrelationship between carbohydrate and lipid metabolism (Glucose-Fatty Acid Cycle). Medicina Sportiva 6:E115-E131, 2002.
45. Randle PJ. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev 14:263-283, 1998.
46. Anderson N, Borlak J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev 60:311-357, 2008.
Otros artículos de Ana M Aransay

Martínez-Chantar M.L., Vázquez-Chantada M., Ariz U., Martínez N., Varela M., Luka Z., Capdevila A., Rodríguez J., Aransay A.M., Matthiesen R., Yang H., Calvisi D. F., Esteller M., Fraga M., Lu S.C., Wagner C. and Mato J.M. Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology 47(4): 119 –1199 (2008)

Hackenberg, M., Sturm, M., Langenberger, D., Falcón-Pérez, J.M. and Aransay, A.M. miRanalyzer: a microRNA detection and analysis tool for next-generation sequencing experiments. REF. REVISTA/LIBRO: Nucleic Acids Research 37, Supp.2 (Web Server issue): W68-W76 (2009)

Rodríguez-Ezpeleta, N., Álvarez-Busto, J., Imaz L, Regueiro, M.,•Azcárate, M.N., Bilbao R., Iriondo, M., Gil A., Estonba A. and•Aransay, A.M. High-density SNP genotyping detects homogeneity of Spanish and French Basques, and confirms their genomic distinctiveness from other European populations. Human Genetics 128(1): 113 – 117 (2010).

Díaz-Peña R., Aransay A.M., Bruges-Armas J., López-Vázquez A., Rodríguez-Ezpeleta N., Mendibil I., Sánchez A., Torre-Alonso J.C., Bettencourt B.F., Mulero J., Collantes E. and López-Larrea C. Fine mapping of major histocompatibility complex in ankylosing spondylitis: association of HLA-DPA1 and HLA-DPB1 region. Arthritis & Rheumatism 63(11):3305-12 (2011)

Rodriguez-Ezpeleta N., Hackenberg M. and Aransay A.M. Bioinformatics for High Throughput Sequencing. Springer, New York, NY, USA, (2012) (Hardcover: ISBN 978-1-4614-0781-2; eBook: SBN 978-1-4614-0782-9). http://dx.doi.org/10.1007/978-1-4614-0782-9, (Book edition and Chapter)

Vandenbroeck K., Alvarez J., Swaminathan B., Alloza I., Matesanz F., Urcelay E., Comabella M., Alcina A., Fedetz M., Ortiz M.A., Izquierdo G., Fernandez O., Rodriguez-Ezpeleta N., Matute C., Caillier S., Arroyo R., Montalban X., Oksenberg J.R., Antigüedad A., Aransay A. A cytokine gene screen uncovers SOCS1 as genetic risk factor for multiple sclerosis. Genes and Immunity 13:21-28 (2012)

Díaz-Peña R., Aransay A.M., Suárez-Álvarez B., Bruges-Armas J., Rodríguez-Ezpeleta N., Regueiro M., Pimentel-Santos F.M., Mulero J., Sánchez A., Collantes E., Queiro R., Ballina J., Alves H. and López-Larrea C. A high density SNP genotyping approach within the 19q13 chromosome region identifies an association of a CNOT3 polymorphism with ankylosing spondylitis. Ann Rheum Dis 71:714-717 (2012)

Mercedes Vazquez-Chantada, Aintzane Gonzalez-Lahera, Ibon Martinez-Arranz, Carmelo Garcia-Monzon, Manuela Maria Regueiro, Juan Luis Garcia-Rodriguez, Karin Anna Schlangen, Iñaki Mendibil, Naiara Rodriguez-Ezpeleta, Juan Jose Lozano, Karina Banasik, Johanne M Justesen, Torben Joergensen, Daniel R Witte, Torsten Lauritzen, Torben Hansen, Oluf Pedersen, Nicolas Veyrie, Karine Clement, Joan Tordjman, Albert Tran, Yannik Le Marchand-Brustel, Xabier Buque, Patricia Aspichueta, Jose Javier Echevarria-Uraga, Antonio Martin-Duce, Joan Caballería, Philippe Gual, Azucena Castro, Jose M Mato, Maria Luz Martinez-Chantar, Ana Maria Aransay. Solute carrier family 2 member 1 (SLC2A1) is involved in the development of Non-Alcoholic Fatty Liver Disease. Hepatology 57(2): 505-514 (2013)

Mosén-Ansorena & Aransay A.M. Bivariate segmentation of SNP-array data for allele-specific copy number analysis in tumour samples. BMC Bioinformatics 14: 84 (2013)

Felix Royo, Karin Schlangen, Laura Palomo, Esperanza Gonzalez, Javier Conde- Vancells, Agustin Berisa, Ana M. Aransay and Juan M. Falcon-Perez
TITULO: Transcriptome of extracellular vesicles released by hepatocytes
REF. REVISTA/LIBRO: PLosONE (PONE-D-13-10983R1, In press 2013)

Para comunicarse con Ana M Aransay mencionar a SIIC como referencia:
amaransay@cicbiogune.es

Autor invitado
13 de agosto, 2013
Descripción aprobada
10 de septiembre, 2013
Reedición siicsalud
10 de febrero, 2014

Acerca del trabajo completo
EL PAPEL DEL TRANSPORTADOR SLC2A1 EN LA PATOGENIA DEL HÍGADO GRASO

Título original en castellano
EL GEN SLC2A1 (SOLUTE CARRIER FAMILY 2 MEMBER1) ESTA IMPLICADO EN EL DESARROLLO DE LA ENFERMEDAD DE HIGADO GRASO NO ALCOHOLICO

Autor


Acceso a la fuente original
Hepatology
http://www3.interscience.wiley.com/cgi-bin/jhome/106570044

El artículo se relaciona estrictamente con las especialidades de siicsalud


ua40317
-->